Selective small-molecule inhibitors of BCL-XL may enhance the efficacy of MLN8237(an Aurora kinase inhibitor) and other targeted chemotherapeutic agents in medulloblastoma and pediatric glioblastoma cells [43]. Here, BCL2L1 is linked to glioblastoma.